Paricalcitol

Hyperparathyroidism, Secondary, Hyperparathyroidism, Secondary, Renal Insufficiency, Chronic + 1 more

Treatment

8 FDA approvals

11 Active Studies for Paricalcitol

Treatment for

Hyperparathyroidism, Secondary

What is Paricalcitol

ParicalcitolThe Generic name of this drug

Treatment SummaryParicalcitol is a type of synthetic vitamin D that helps lower parathyroid hormone levels. It is used to prevent and treat high levels of parathyroid hormone in people with chronic kidney disease.

Zemplaris the brand name

Paricalcitol Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Zemplar

Paricalcitol

1998

Approved as Treatment by the FDA

Paricalcitol, also known as Zemplar, is approved by the FDA for 8 uses which include Hyperparathyroidism, Secondary and Hyperparathyroidism, Secondary .

Hyperparathyroidism, Secondary

Renal Insufficiency, Chronic

Chronic Kidney Disease, Stage 3 (Moderate)

Secondary Hyperparathyroidism (SHPT)

Stage 4 Chronic Kidney Disease

Stage 5 Chronic Kidney Disease (CKD)

prophylaxis of secondary hyperparathyroidism

Effectiveness

How Paricalcitol Affects PatientsSecondary hyperparathyroidism is a condition in which the body has too much of the hormone parathyroid hormone (PTH) due to inadequate levels of active vitamin D. Vitamin D helps form and maintain normal bones and is created in the skin and from food. Vitamin D needs to be changed in the liver and kidneys before it works properly. When the kidneys are not healthy, the activation of vitamin D is lowered, causing PTH to rise. This leads to problems with calcium and phosphorus levels in the body and can cause renal osteodystrophy (loss of bone mass). Paricalcitol is a drug that helps regulate P

How Paricalcitol works in the bodyParicalcitol is a man-made version of vitamin D that works to reduce parathyroid hormone levels. It does this by binding to the vitamin D receptor and activating pathways that respond to vitamin D. This helps stop the body from making too much parathyroid hormone.

When to interrupt dosage

The suggested dosage of Paricalcitol is contingent upon the determined disorder, including Hyperparathyroidism, Secondary, Hemodialysis and Stage 4 Chronic Kidney Disease. The measure of dosage differs as outlined by the technique of delivery outlined in the table below.

Condition

Dosage

Administration

Hyperparathyroidism, Secondary

, 0.005 mg/mL, 0.002 mg/mL, 0.001 mg, 0.002 mg, 0.004 mg, 1.0 mg, 2.0 mg, 4.0 mg, 0.01 mg/mL

, Intravenous, Injection, solution, Injection, solution - Intravenous, Injection, Injection - Intravenous, Oral, Capsule, liquid filled, Capsule, liquid filled - Oral, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Capsule, Capsule - Oral, Solution, Solution - Intravenous

Renal Insufficiency, Chronic

, 0.005 mg/mL, 0.002 mg/mL, 0.001 mg, 0.002 mg, 0.004 mg, 1.0 mg, 2.0 mg, 4.0 mg, 0.01 mg/mL

Hyperparathyroidism, Secondary

, 0.005 mg/mL, 0.002 mg/mL, 0.001 mg, 0.002 mg, 0.004 mg, 1.0 mg, 2.0 mg, 4.0 mg, 0.01 mg/mL

Stage 4 Chronic Kidney Disease

, 0.005 mg/mL, 0.002 mg/mL, 0.001 mg, 0.002 mg, 0.004 mg, 1.0 mg, 2.0 mg, 4.0 mg, 0.01 mg/mL

Warnings

There are 20 known major drug interactions with Paricalcitol.

Common Paricalcitol Drug Interactions

Drug Name

Risk Level

Description

Sucralfate

Major

The serum concentration of Sucralfate can be increased when it is combined with Paricalcitol.

1alpha,24S-Dihydroxyvitamin D2

Moderate

The risk or severity of adverse effects can be increased when Paricalcitol is combined with 1alpha,24S-Dihydroxyvitamin D2.

1alpha-Hydroxyvitamin D5

Moderate

The risk or severity of adverse effects can be increased when Paricalcitol is combined with 1alpha-Hydroxyvitamin D5.

Acetyldigitoxin

Moderate

The risk or severity of ventricular arrhythmias and Cardiac Arrhythmia can be increased when Paricalcitol is combined with Acetyldigitoxin.

Acetyldigoxin

Moderate

The risk or severity of ventricular arrhythmias and Cardiac Arrhythmia can be increased when Paricalcitol is combined with Acetyldigoxin.

image of a doctor in a lab doing drug, clinical research

Paricalcitol Novel Uses: Which Conditions Have a Clinical Trial Featuring Paricalcitol?

Fifteen clinical trials are assessing the potential of Paricalcitol to control Stage 4 Chronic Kidney Disease, Chronic Kidney Disease Stage 3 (Moderate) and Hemodialysis.

Condition

Clinical Trials

Trial Phases

Renal Insufficiency, Chronic

3 Actively Recruiting

Phase 2, Phase 1

Hyperparathyroidism, Secondary

4 Actively Recruiting

Phase 3, Not Applicable

Hyperparathyroidism, Secondary

0 Actively Recruiting

Stage 4 Chronic Kidney Disease

6 Actively Recruiting

Phase 4, Phase 1, Phase 2, Not Applicable

Paricalcitol Reviews: What are patients saying about Paricalcitol?

4.7Patient Review

9/1/2008

Paricalcitol for Hyperparathyroidism caused by Chronic Kidney Failure

3.3Patient Review

3/26/2010

Paricalcitol for Hyperparathyroidism caused by Chronic Kidney Failure

3Patient Review

6/27/2011

Paricalcitol for Hyperparathyroidism caused by Chronic Kidney Failure

image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about paricalcitol

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is paricalcitol a steroid?

"It is a seco-cholestane and a hydroxy seco-steroid derivative.

Paricalcitol is a seco-cholestane and a hydroxy seco-steroid. It acts as an antiparathyroid drug. It is a seco-cholestane and a hydroxy seco-steroid derivative."

Answered by AI

What is another name for paricalcitol?

"Zemplar (paricalcitol) Injection is a form of vitamin d that is indicated for the prevention and treatment of secondary hyperparathyroidism associated with chronic kidney disease Stage 5."

Answered by AI

Is paricalcitol a vitamin D?

"A synthetic form of vitamin D2 called paricalcitol was created to treat secondary hyperthyroidism connected to chronic renal failure."

Answered by AI

What is paricalcitol prescribed for?

"Paricalcitol is used to treat and prevent hyperparathyroidism in patients with chronic kidney disease who are on dialysis. Hyperparathyroidism is a condition caused by the parathyroid glands located in the neck making too much parathyroid hormone (PTH)."

Answered by AI

Clinical Trials for Paricalcitol

Have you considered Paricalcitol clinical trials? We made a collection of clinical trials featuring Paricalcitol, we think they might fit your search criteria.

Have you considered Paricalcitol clinical trials? We made a collection of clinical trials featuring Paricalcitol, we think they might fit your search criteria.